© 2022 Sema4 OpCo, Inc. All rights reserved.
Advanced molecular profiling technologies
Sema4 Signal WES/WTS and Sema4 Signal PanCancer integrate tumor-normal matched WES with WTS to deliver the most comprehensive molecular insights:
-
-
-
Hybrid capture-based next generation sequencing of 18,500 genes
-
-
-
-
-
Run on the Illumina NovaSeq 6000 system in our CLIA-certified, CAP-accredited lab
-
-
-
-
-
Reporting of:
-
-
- SNVs, In/Dels
- CNVs
- Arm and whole chromosome aneuploidies
- Gene fusions (RNA)
- Splice variants (RNA)
-
-
-
Assessment of:
-
-
- TMB
- MSI
- PD-L1 antibodies 22C3 and SP142
-
-
-
Tumor-normal sequencing to enable differentiation between somatic and germline alterations
-
-
-
-
-
Target sequencing depth:
-
-
- Tumor: 250X
- Normal: 100X
- RNA: 100M reads
Connect with us today